TingSheng Medical Completes Nearly RMB 100 Million Series B+ Financing Led by Efung Capital

Investment Circle (ID: pedaily2012) June 25th, by reporter, TINGSN announced the completion ofNearly 100 Million Yuan in B+ Round Financing, byYifeng Capital Leads the Investment, with Existing Shareholders Qiming Venture Capital and Huangpu Pharmaceutical Fund Following SuitThis round of financing was served by Xingqiao Capital as the exclusive financial advisor.

Notably, TINGSN successfully completed China's first 4D ICE human clinical study on April 29. This breakthrough not only signifies a critical leap for Chinese companies in the cardiovascular interventional imaging field, moving from "catching up" to "running alongside," but also demonstrates that TINGSN has established a mature full-chain independent innovation system, progressing from the first domestically produced 2D ICE catheter to 4D ICE.

The funds from this round of financing will further increase the research and development and clinical investment in 4D intracardiac echocardiography (4D ICE), making full preparations for the upcoming process mass production.

TINGSN Technology CEO Zhang Dongyu4D ICE represents the pinnacle of cardiovascular interventional imaging technology. The team’s successful development of this product within four years, along with the smooth completion of the first human clinical trial, is due to TINGSN's solid foundation in underlying technologies, sufficient R&D investment, and outstanding, highly efficient team execution. The successful development of 4D ICE has injected strong momentum into the company's future growth, significantly enhancing its competitiveness in the global market. This marks a solid step forward for the team in achieving the vision of "becoming an influential medical device brand made in China."

Fan Rongkui, Managing Director of Efung CapitalIntracardiac Echocardiography (ICE), as the "eyes" for various cardiac electrophysiology and structural heart interventional procedures, has been increasingly gaining clinical recognition. The overall technological barriers for this product are high, and it is currently on the eve of domestic substitution in China. The TINGSN team possesses strong capabilities in combining medical expertise with engineering, innovation, deep technical accumulation, engineering transformation, and rich commercialization experience with execution power. Its core product, 2D ICE, is the first domestically produced device in China to have received certification through the medical device green channel, achieving rapid commercial success. The 4D ICE was the first to complete its initial human study and has made significant breakthroughs in the independent development of the underlying core component supply chain, which is expected to maximize its cost and differentiation advantages in future competition. Evolve Capital looks favorably upon TINGSN as a leader in the intracardiac echocardiography field, continuing to drive intelligent advancements within the industry.

Guo Kai, Head of StarBridge CapitalTINGSN, as a leading enterprise in China's intracardiac ultrasound field, has achieved several "zero breakthroughs" in the past 7 years — from 2D ICE to 4D ICE, from being the first domestically-produced company to independently research and produce transducers to completing the ASIC chip tape-out. It has realized true domestic substitution in the truest sense, driving technological leadership alongside the rapid growth of China’s electrophysiology-related fields. We believe TINGSN will continue to shine on an even broader stage!

TINGSN TechnologyFounded by senior scientists in the ultrasound field, cardiologists, and serial entrepreneurs, with its headquarters in Nanjing, China, and research and development centers in both China and the US. Led by top talents of National Key Projects (Class A, returned overseas Ph.D.), an international R&D team has been established, collaborating deeply with globally renowned clinical teams and top acoustic research institutions in China. The company focuses on technological innovation in the application of ultrasound for cardiac electrophysiology and structural heart diseases. By integrating imaging, mapping, and ablation energy technologies, it is committed to providing more effective treatments for patients with heart disease.